Rhythm Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Rhythm Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 65.6% bzw. 44.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 67% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -62.6% betragen.

Wichtige Informationen

65.5%

Wachstumsrate der Gewinne

67.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	0%
Wachstumsrate der Einnahmen	44.9%
Zukünftige Eigenkapitalrendite	-67.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	19 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BMV:RYTM * - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	348	-26	12	142	7
12/31/2025	180	-160	-126	-111	9
12/31/2024	121	-275	-266	-195	9
3/31/2024	92	-274	-182	-140	N/A
12/31/2023	77	-185	-142	-136	N/A
9/30/2023	62	-186	-146	-141	N/A
6/30/2023	44	-182	-164	-159	N/A
3/31/2023	34	-181	-161	-156	N/A
12/31/2022	24	-181	-174	-173	N/A
9/30/2022	17	-181	-173	-180	N/A
6/30/2022	13	-176	-166	-173	N/A
3/31/2022	5	-166	-160	-166	N/A
12/31/2021	3	-70	-139	-146	N/A
9/30/2021	1	-62	-135	-135	N/A
6/30/2021	0	-60	-122	-122	N/A
3/31/2021	0	-56	-120	-119	N/A
12/31/2020	N/A	-134	-122	-122	N/A
9/30/2020	N/A	-132	-125	-125	N/A
6/30/2020	N/A	-134	-132	-132	N/A
3/31/2020	N/A	-146	-130	-127	N/A
12/31/2019	N/A	-141	-126	-123	N/A
9/30/2019	N/A	-133	-115	-112	N/A
6/30/2019	N/A	-115	-99	-95	N/A
3/31/2019	N/A	-87	-83	-82	N/A
12/31/2018	N/A	-74	-63	-62	N/A
9/30/2018	N/A	-59	-49	-49	N/A
6/30/2018	N/A	-53	-41	-40	N/A
3/31/2018	N/A	-47	-34	-34	N/A
12/31/2017	N/A	-38	N/A	-29	N/A
9/30/2017	N/A	-36	N/A	-28	N/A
6/30/2017	N/A	-32	N/A	-24	N/A
3/31/2017	N/A	-30	N/A	-24	N/A
12/31/2016	N/A	-29	N/A	-23	N/A
9/30/2016	N/A	-27	N/A	-21	N/A
6/30/2016	N/A	-23	N/A	-18	N/A
3/31/2016	N/A	-17	N/A	-13	N/A
12/31/2015	N/A	-12	N/A	-7	N/A
9/30/2015	N/A	-6	N/A	-4	N/A
6/30/2015	N/A	-3	N/A	-4	N/A
3/31/2015	N/A	-5	N/A	-6	N/A
12/31/2014	N/A	-6	N/A	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RYTM * wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (7.8%).

Ertrag vs. Markt: RYTM * wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: RYTM * wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: RYTM *Die Einnahmen des Unternehmens (44.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt MX (7% pro Jahr).

Hohe Wachstumseinnahmen: RYTM *Die Einnahmen des Unternehmens (44.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RYTM * wird voraussichtlich in 3 Jahren unrentabel sein.

Rhythm Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast to breakeven in 2026

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Recent updates

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for Imcivree® (Setmelanotide) in Patients as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Index

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old with Bardet Biedl Syndrome

Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Forecast to breakeven in 2026

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rhythm Pharmaceuticals, Inc. Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

Rhythm Pharmaceuticals, Inc. Announces Approval of IMCIVREE®? Setmelanotide Solution for Weight Management in Adult and Pediatric Patients

First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.05 loss in 1Q 2022)

Full year 2022 earnings released: US$3.48 loss per share (vs US$1.40 loss in FY 2021)

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces ?Imcivree (Setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology

Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-Term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity At Obesityweek® and Plans to Initiate Phase 3 Trial in Early 2023

Rhythm Pharmaceuticals, Inc. Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA

Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands the Marketing Authorization for Imcivree(R) (Setmelanotide)

Second quarter 2022 earnings released: US$0.89 loss per share (vs US$0.70 loss in 2Q 2021)

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

NICE Recommends Rhythm’s IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency

Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. Announces That European Commission Authorized Variation for Imcivree (Setmelanotide) to Allow for Dosing in Patients with POMC or LEPR Deficiency with Renal Impairment

Rhythm Pharmaceuticals, Inc. Announces FDA Approval of IMCIVREE for Use in Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Presents Initial Data from Long-Term Extension Trial Evaluating Setmelanotide in Rare Genetic Diseases of Obesity at ENDO 2022

Rhythm Pharmaceuticals, Inc. Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome At the Pediatric Endocrine Society 2022 Virtual Annual Meeting

Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity

Forecast to breakeven in 2024

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

Rhythm Pharmaceuticals, Inc. Announces Executive Promotions

Rhythm Pharmaceuticals, Inc. Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)

Rhythm Pharmaceuticals, Inc. Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Patients with Genetic Obesity Disorder

High number of new directors

Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain

Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl and Alström Syndromes

Rhythm Pharmaceuticals, Inc Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity

Rhythm Pharmaceuticals, Inc. Announces European Commission Authorization of IMCIVREE

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Growth Index

Forecast to breakeven in 2024

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken